Ownership & editorial policy

Peptide Press is owned by the principals of Peptinexia LLC, which also provides financial support for the publication. Editorial content does not provide medical advice, dosing guidance, administration instructions, or recommendations for the use or purchase of any compound.

What we cover

Peptide Press is an editorial publication covering peptide research, analytical testing, clinical studies, regulation, and industry developments. We report on the field as a trade publication would: studies, testing methodology, trial status, and regulatory action, with citations to primary sources.

What we do not do

Editorial content does not provide medical advice, dosing guidance, administration or reconstitution instructions, therapeutic recommendations, or guidance on how to use or purchase any compound. We do not publish protocols. Articles about a compound do not link to any page selling that compound.

Our relationship with Peptinexia

Peptide Press is owned by the principals of Peptinexia LLC, a Napa Valley peptide company, which also provides financial support for the publication. Where Peptinexia is referenced, that connection is disclosed. Any link to Peptinexia is a single, brand-level reference — never a product link tied to the subject of an article.

Sourcing standard

We cite primary sources — peer-reviewed studies, trial registries, and agency documents — rather than secondary summaries. We distinguish preclinical from clinical evidence, and we report limitations, null results, and enforcement actions even when they are unflattering to the field.

Corrections

We correct errors promptly and note material changes. To report one, contact the editorial desk.